FDA Approved: WELLBUTRIN XL — Supplemental Application (Bausch Health US LLC)

View source ↗

Summary

The FDA approved a supplemental application for WELLBUTRIN XL (bupropion hydrochloride) submitted by Bausch Health US LLC under NDA021515.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Seasonal Affective Disorder

Drugs mentioned

• WELLBUTRIN XL (Bupropion hydrochloride)

Snippet

SUPPL AP for WELLBUTRIN XL (BUPROPION HYDROCHLORIDE)